恩度联合信迪利单抗注射液治疗晚期结直肠癌的效果及其对血清CA199、CEA、CYFRA21-1水平的影响

Effect of Endu combined with Sindiglimab injection in the treatment of advanced colorectal cancer and its influence on serum CA199,CEA,CYFRA21⁃1 levels

目的探讨恩度联合信迪利单抗注射液治疗晚期结直肠癌的效果及其对血清糖类抗原199(CA199)、癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)水平的影响。方法选取2019年7月至2022年7月安徽淮南朝阳医院肿瘤放疗科收治的102例晚期结直肠癌患者,按照治疗方法将患者分为对照组(n=51,接受恩度治疗)和观察组(n=51,接受恩度联合信迪利单抗注射液治疗)。比较两组的临床疗效、不良反应发生情况、血清CA199、CEA、CYFRA21-1水平。结果与对照组相比,观察组的疾病控制率明显提高,差异有统计学意义(χ^(2)=12.421,P<0.05)。观察组的不良反应总发生率明显低于对照组,差异有统计学意义(P<0.05)。观察组的血清CA199、CEA、CYFRA21-1水平低于对照组,差异有统计学意义(t=0.649,5.421,0.413,8.464,0.739,2.817,P<0.05)。治疗后,观察组的PS评分和身体质量指数均明显高于对照组,差异有统计学意义(t=0.374,6.836,1.056,2.336,P<0.05)。结论恩度联合信迪利单抗注射液治疗晚期结直肠癌的临床效果显著,减少不良反应的发生,降低肿瘤标志物水平,提高患者生活质量。

Objective To investigate the effect of Endu combined with Sindiglimab injection in the treatment of advanced colorectal cancer and its influence on the levels of serum cancer antigen 199(CA199),alpha fetoprotein(CEA)and cytokeratin 19 fragment(CYFRA21⁃1).Methods From July 2019 to July 2022,102 patients with advanced colorectal cancer admitted to the Cancer Radiotherapy Department of Anhui Huainan Chaoyang Hospital were divided into the control group(n=51,receiving Endu therapy)and the observation group(n=51,receiving Endu combined with Sindiglimab injection)according to the treatment methods.The clinical efficacy,adverse reactions,serum CA199,CEA,CYFRA21⁃1 levels were compared between the two groups.Results Compared with the control group,the disease control rate in the observation group was significantly improved(χ^(2)=12.421,P<0.05).The total incidence of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05).The levels of serum CA199,CEA,CYFRA21⁃1 in the observation group were lower than those in the control group(t=0.649,5.421,0.413,8.464,0.739,2.817,P<0.05).After treatment,the PS score and body mass index in the observation group were significantly higher than those in the control group(t=0.374,6.836,1.056,2.336,P<0.05).Conclusion Endu combined with Sindiglimab injection has a significant clinical effect in the treatment of advanced colorectal cancer,reducing the occurrence of adverse reactions,and the level of tumor markers,and improving the quality of life of patients.